v2.4.0.6
CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2010
Dec. 31, 2009
Current assets:    
Cash and cash equivalents $ 70,052 $ 105,255
Short-term investments 402,301 469,057
Contracts receivable 1,242 10,899
Inventories 2,484 2,768
Other current assets 7,058 8,147
Total current assets 483,137 596,126
Property, plant and equipment, net 35,703 27,338
Licenses, net 12,288 14,542
Patents, net 15,821 15,909
Deposits and other assets 3,528 3,269
Total assets 550,477 657,184
Current liabilities:    
Accounts payable 6,523 4,696
Accrued compensation 6,831 7,135
Income taxes payable   7,323
Accrued liabilities 12,389 12,339
Current portion of long-term obligations 5,645 4,270
Current portion of deferred contract revenue 74,502 75,681
Total current liabilities 105,890 111,444
Long-term deferred contract revenue 50,413 107,097
2 5/8 percent convertible subordinated notes 132,895 125,100
Long-term obligations, less current portion 5,720 11,478
Long-term financing obligation 10,147  
Investment in Regulus Therapeutics Inc. 870  
Total liabilities 305,935 355,119
Stockholders' equity:    
Common stock, $0.001 par value; 200,000,000 shares authorized, 99,393,780 and 98,850,934 shares issued and outstanding at December 31, 2010 and 2009, respectively 99 99
Additional paid-in capital 1,000,181 985,620
Accumulated other comprehensive income 949 2,153
Accumulated deficit (756,687) (696,150)
Total Isis Pharmaceuticals, Inc. stockholders' equity 244,542 291,722
Noncontrolling interest in Regulus Therapeutics Inc.   10,343
Total stockholders' equity 244,542 302,065
Total liabilities and stockholders' equity $ 550,477 $ 657,184